GlassScriptPhysician profile
Mark S Elliott
NPI 1184724718
$867.99
in general payments reported to CMS, 2019-2025
13 companies · $66.10 in 2025
The $66.10 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $55.36 · 2021: $106 · 2022: $211 · 2023: $147 · 2024: $82.58 · 2025: $66.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $295.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $215.28 | 2019-2022 | |
| Smith+Nephew, INC. | $141.81 | 2019 | |
| Abbvie INC. | $106.49 | 2023-2025 | |
| Sientra, INC. | $100.77 | 2019-2021 | |
| Organogenesis INC. | $63.45 | 2021-2023 | Puraply |
| Becton, Dickinson and Company | $62.04 | 2024 | Venclose Maven Catheter |
| Triad Life Sciences INC. | $47.92 | 2022 | |
| Integra Lifesciences Corporation | $43.11 | 2023 | Integra, Surgimend, Integra Dermal Regeneration Template |
| Lilly USA, LLC | $21.63 | 2025 | Ebglyss |
| Convatec INC. | $20.61 | 2023 | |
| Sun Pharmaceutical Industries INC. | $17.64 | 2021 | |
| Galderma Laboratories, L.P. | $15.35 | 2025 | |
| Kerecis Limited | $11.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Elliott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.